Adgero Biopharmaceuticals

Adgero Biopharmaceuticals Holdings, Inc. operates as a privately-owned biopharmaceutical firm with a focus on developing a portfolio by progressing its unique advanced photodynamic therapy ('PDT') platform that has wide-ranging applicability in treating severe skin cancer conditions. The primary product in development, REM-001 Therapy, has undergone previous evaluation in four Phase 2 and/or Phase 3 clinical studies involving patients with cutaneous metastatic breast cancer ('CMBC') who had previously undergone chemotherapy and did not respond to radiation therapy. Successful completion of a Phase 3 trial involving individuals with CMBC may result in the approval of REM-001 Therapy.